Joint initiative for drug development

The company has invested in biotechnology company of Pablo de Olavide University, Seville

Biomedal, with over 20 years of experience in the biotechnological industry, has invested in the biotechnology company Olavide Neuron STX of the Pablo de Olavide University. This collaboration favors the development of a drug to treat the consequences of neurodegenerative diseases such as Alzheimer and Huntington's chorea. The drug has proven to be safe when administered to patients of other illnesses, meaning it will go straight to clinical trial phase 2, thus shortening risks and market delivery time significantly.

This business project, supported by the Pablo de Olavide University and promoted by the Industrial Liaison Office (ILO), includes the collaboration of Biomedal. This biotechnology company, which develops and supplies analytical laboratory services and innovative products for the control of disease progressions, has more than 1000 sqm of state-of-the-art facilities in Camas’ Parque Plata (Seville) for research, development and manufacture of in vitro diagnostic products and analytical food services, as well as management, marketing and sales teams at the Cartuja Technological Science Park, also in Seville.

Source: Europa Press